It’s time to put your pets to work in your very own independent film showing how animals can help people feel better.
Connecticut’s nonprofit psychotherapy and educational organization, Soul Friends, Inc, is hosting their first pet-themed film festival on Saturday, November 21 at Showcase Cinemas in North Haven from 10 am to noon.

Soul Friends helps at-risk children with therapy animals and other interactive activities. Their services include dog training for special needs children, equine assisted psychotherapy and crisis response therapy dogs.
To enter the Petflix Film Festival, submit a video under 5 minutes or within the 5-10 minute category. Film shorts will …read more

Food, Inc. is a documentary about how our food has changed so much over the past 50 years, despite the pastoral scenes often depicted on products. It’s also about how big food corporations don’t want people to know the full truth. Filmmaker Robert Kenner worked to bring Food, Inc. to the screen for more than six years. He was denied interviews he wanted.

Rotten Tomatoes review site has given the film a Certified Fresh rating, so it’s one to watch in my book.
According to Kenner, the “enormous buying power of the fast food industry” transformed food production in the US. He …read more

The makers of EDY’s products – Dreyer’s Grand Ice Cream, Inc. – is extending its huge thanks o citizens throughout the Northeast that stopped in to their local Stop & Shop or Giant Food store on May 3 to support Scoop Day and the fight against childhood cancer.

More than $120,000 was raised at Stop & Shop and Giant stores throughout New England, New York, New Jersey, Delaware, Virginia, Washington D.C., and Maryland on the one day where shoppers donated $1 for a scoop of SLOW CHURNED light ice cream or $3 for a scoop of SLOW CHURNED light ice …read more

A new experimental drug has been found by Oregon Health & Science University (OHSU) Cancer Institute researchers to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).
The said new drug candidate – SGX393 – has been found to inhibit most resistant mutations — including T315I — both in mouse models and in patient cells in laboratory studies.
This drug candidate could build on the legacy of Gleevec, which has been the gold standard for treating this leukemia and was developed by Brian Druker, M.D., director of the OHSU Cancer Institute.
Despite Gleevec’s success, some CML patients develop resistance …read more